A new radioactive treatment called actinium-225 successfully eliminated ovarian cancer tumors in 40% of laboratory tests and achieved 80% survival rates, according to research published in Science Advances in 2026. The treatment uses a targeted antibody to deliver powerful alpha particles directly to cancer cells while minimizing damage to healthy tissue. However, this is early-stage laboratory research in mice, and human clinical trials are still needed before this treatment becomes available to patients.
Scientists have developed a new way to fight ovarian cancer using a radioactive particle called actinium-225 that targets cancer cells specifically. In laboratory tests, this treatment eliminated tumors completely in 40% of cases and helped 80% of test subjects survive. The treatment works by attaching to a protein found on ovarian cancer cells, then delivering powerful radiation directly to the cancer while leaving healthy tissue mostly unharmed. According to Gram Research analysis, this targeted approach could offer new hope for patients whose cancers have become resistant to standard treatments.
Key Statistics
A 2026 research article in Science Advances found that FOLR1-targeted actinium-225 alpha-particle therapy achieved 40% complete tumor elimination and 80% survival in laboratory ovarian cancer models.
According to 2026 research published in Science Advances, the targeted alpha-particle treatment caused tumor-specific double-stranded DNA damage while producing no obvious toxicity in normal tissues.
Gram Research analysis of 2026 preclinical data showed that estimated human dosimetry calculations indicated high absorbed radiation dose for ovarian cancer tumors with minimal absorbed dose for healthy tissues, suggesting safety potential.
The Quick Take
- What they studied: Whether a new radioactive treatment called actinium-225, designed to target ovarian cancer cells, could effectively kill tumors while staying safe for the body
- Who participated: Laboratory tests using ovarian cancer cells grown in mice (xenografts), not human patients yet
- Key finding: The treatment achieved 40% complete tumor elimination, 80% survival rate, and caused tumor-specific DNA damage without obvious harm to normal tissues
- What it means for you: This is early-stage research showing promise for a future treatment option for ovarian cancer, particularly for cancers that have resisted other treatments. However, human clinical trials are still needed before this becomes available to patients.
The Research Details
Researchers created a new treatment by combining an antibody (a protein that acts like a guided missile) with actinium-225, a radioactive element that releases powerful alpha particles. The antibody was designed to recognize and stick to FOLR1, a protein commonly found on ovarian cancer cells. They tested this combination in laboratory mice with human ovarian cancer tumors to see if it could find and destroy the cancer. They used imaging technology called PET scans to track where the treatment went in the body and measured how well it worked at shrinking tumors.
The researchers carefully monitored the mice to see if the treatment caused damage to healthy organs and tissues. They also calculated what doses would be safe and effective if this treatment were eventually used in humans, based on the animal data. This type of research is called preclinical testing and is an important step before any new cancer treatment can be tested in human patients.
This research approach is important because it shows how scientists can design treatments that specifically target cancer cells while minimizing harm to healthy tissue. Alpha particles are particularly powerful at destroying cancer cells because they release intense energy in a very small area. By attaching this powerful particle to an antibody that recognizes cancer cells, researchers created a treatment that acts like a precision weapon against ovarian cancer.
This study was published in Science Advances, a highly respected scientific journal. The research used established laboratory methods and imaging technology to track results. However, this is preclinical research (laboratory and animal testing), not human trials, so results may not translate directly to human patients. The study did not specify the exact number of tumors or mice tested, which would help readers understand the scope better. The promising results warrant further investigation but should not be considered proven in humans yet.
What the Results Show
The FOLR1-targeted actinium-225 treatment showed remarkable effectiveness in laboratory tests. Imaging scans confirmed that the treatment successfully found and accumulated in ovarian cancer tumors, with high tumor-specific uptake. The treatment achieved marked tumor regression (significant shrinking), with 80% of test subjects surviving the treatment period and 40% experiencing complete tumor elimination—meaning the tumors disappeared entirely.
The treatment worked by causing double-stranded DNA damage specifically in cancer cells, which is the mechanism that kills the cancer. Importantly, researchers observed no obvious toxicity or damage to normal tissues and organs during the study. When scientists calculated what human doses would be needed based on the animal data, they found that tumors would receive high radiation doses while healthy tissues would receive minimal doses, suggesting the treatment could be safe for human use.
The research demonstrated that the antibody component of the treatment successfully targeted FOLR1 protein on cancer cells with high specificity. The combination of the targeting antibody with the alpha-particle radiation proved more effective than either component alone would likely be. The treatment showed consistent results across the test subjects studied, suggesting reliability of the approach.
This research builds on growing interest in alpha-particle therapy for hard-to-treat cancers. Previous research has shown that targeted therapies—treatments designed to attack specific features of cancer cells—often work better than traditional chemotherapy. This study represents one of the first successful demonstrations of combining alpha-particle therapy with FOLR1 targeting specifically for ovarian cancer, filling a gap in treatment options for patients whose cancers have become resistant to standard therapies.
This research was conducted in laboratory settings and in mice, not in human patients. Results in animals don’t always translate to humans due to differences in metabolism and immune response. The study did not specify exact sample sizes or statistical analysis details. The treatment has not yet been tested for long-term side effects in humans. Ovarian cancer is complex and varies between patients, so results may differ in real-world human populations. Before this treatment could be used in patients, it would need to go through multiple phases of human clinical trials to confirm safety and effectiveness.
The Bottom Line
This research is too early-stage to recommend for patient use. It represents a promising laboratory discovery that warrants advancement to human clinical trials. Patients with ovarian cancer should continue working with their oncologists on proven treatment options. Healthcare providers should monitor developments in alpha-particle therapy research for potential future applications. Confidence level: This is preliminary evidence from preclinical research.
Ovarian cancer patients and their families should be aware of this development as a potential future option, especially those with treatment-resistant cancers. Oncologists and cancer researchers should follow this work as it advances toward clinical trials. Healthcare policy makers should consider supporting further research in this promising area. People without ovarian cancer do not need to take action based on this research at this time.
If this treatment advances to human clinical trials in the near future, it would typically take 5-10 years of testing before potential FDA approval and availability to patients. Early-phase trials would begin with small groups of patients to confirm safety. Later trials would test effectiveness in larger populations. Even with successful trials, availability would initially be limited to specialized cancer centers.
Frequently Asked Questions
Is there a new cure for ovarian cancer?
A promising new treatment called actinium-225 alpha-particle therapy showed 40% complete tumor elimination in laboratory tests published in 2026. However, this is early-stage research in mice, not yet tested in human patients, so it’s not available as a treatment yet.
How does actinium-225 therapy target cancer cells?
The treatment uses an antibody that recognizes FOLR1 protein on ovarian cancer cells, delivering radioactive actinium-225 directly to tumors. This targeted approach concentrates powerful radiation on cancer while sparing healthy tissue.
When will this ovarian cancer treatment be available to patients?
This laboratory research must advance through human clinical trials before potential approval, typically taking 5-10 years. Early trials would begin with small patient groups to confirm safety before larger effectiveness studies.
What makes this treatment different from current ovarian cancer therapies?
This treatment uses alpha-particle radiation targeted specifically to cancer cells, offering a precision approach for treatment-resistant ovarian cancers. Traditional chemotherapy affects more cells broadly, whereas this targets specific cancer proteins.
Is this treatment safe for ovarian cancer patients?
Laboratory data showed no obvious toxicity to normal tissues, and dosimetry calculations suggest safety potential for humans. However, human clinical trials are required to confirm safety and effectiveness before clinical use.
Want to Apply This Research?
- Users interested in ovarian cancer research developments could track clinical trial announcements and research milestones related to FOLR1-targeted alpha-particle therapy, noting publication dates and trial phase updates
- Set reminders to discuss emerging treatment options with your oncologist during regular appointments, and bookmark reliable sources like ClinicalTrials.gov to monitor when human trials for this treatment become available
- Create a long-term tracking system for new cancer therapy research, logging publication dates, trial phases, and institutional announcements to stay informed about treatment advances relevant to your condition
This article describes early-stage laboratory research that has not yet been tested in human patients. The findings are promising but preliminary. This information is for educational purposes only and should not be considered medical advice. Ovarian cancer patients should continue working with their oncology team on proven treatment options and discuss any new research developments during their regular appointments. Do not delay or replace current cancer treatment based on this research. Always consult with qualified healthcare providers before making any medical decisions.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.